Literature DB >> 17145806

Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis.

Cornelia Leo1, Lars-Christian Horn, Cora Rauscher, Bettina Hentschel, Andre Liebmann, Guido Hildebrandt, Michael Höckel.   

Abstract

PURPOSE: Physiologically, hypoxia induces the expression of erythropoietin (Epo) in adult kidney cells. Epo, in turn, acts on the Epo receptor (EpoR) in RBC precursors to stimulate growth and prevent apoptosis. Because hypoxia plays a major role in the malignant progression of tumors and Epo and its receptors have also been detected in malignant tumors, we investigated the expression of Epo and EpoR and their relationship with hypoxia, proliferation, apoptosis, and clinicopathologic variables in cervical cancer. EXPERIMENTAL
DESIGN: Intratumoral oxygen measurement and needle biopsies of the tumors were done in 48 patients with cervical cancer. The obtained tissue was analyzed by immunohistochemistry with antibodies against Epo, EpoR, and Ki-67 as well as by terminal deoxynucleotidyl transferase-mediated deoxyuracil triphosphate nick-end labeling assays.
RESULTS: Epo and EpoR were expressed in 88% and 92% of samples, respectively. Cervical cancers with higher Epo expression showed a significantly reduced overall survival (3 years, 50.0% versus 80.6%; P = 0.0084). Epo and EpoR expression correlated significantly with apoptosis (r = 0.49, P = 0.001 and r = 0.36, P = 0.021). Furthermore, EpoR expression correlated significantly with tumor size (r = 0.32, P = 0.032) and was significantly associated with the presence of lymphovascular space involvement (P = 0.037). However, we observed no correlation between Epo or EpoR expression and intratumoral hypoxia, although in well-oxygenated tumors, EpoR localized significantly more often to the invasion front (P = 0.047).
CONCLUSIONS: This study analyzes Epo/EpoR expression and their relationship with intratumoral pO(2) levels as well as with survival in patients with cervical cancer. The data suggest a critical role of the endogenous Epo/EpoR system in cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17145806     DOI: 10.1158/1078-0432.CCR-06-1285

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

Review 1.  Erythropoietin receptor response circuits.

Authors:  Don M Wojchowski; Pradeep Sathyanarayana; Arvind Dev
Journal:  Curr Opin Hematol       Date:  2010-05       Impact factor: 3.284

Review 2.  Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents.

Authors:  Charles L Bennett; Stephen Y Lai; Michael Henke; Sara E Barnato; James O Armitage; Oliver Sartor
Journal:  Arch Intern Med       Date:  2010-09-13

3.  Erythropoietin and erythropoietin receptor in hepatocellular carcinoma: correlation with vasculogenic mimicry and poor prognosis.

Authors:  Zhihong Yang; Baocun Sun; Xiulan Zhao; Bing Shao; Jindan An; Qiang Gu; Yong Wang; Xueyi Dong; Yanhui Zhang; Zhiqiang Qiu
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

Review 4.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.

Authors:  S R McKeown
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

5.  Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.

Authors:  Lynda A Szczech; Huiman X Barnhart; Jula K Inrig; Donal N Reddan; Shelly Sapp; Robert M Califf; Uptal D Patel; Ajay K Singh
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

6.  Expression of bcl-2 is associated with microvessel density in olfactory neuroblastoma.

Authors:  Marc Diensthuber; Marc Potinius; Thomas Rodt; Alexandru C Stan; Hans-J Welkoborsky; Madjid Samii; Jonas Schreyögg; Thomas Lenarz; Timo Stöver
Journal:  J Neurooncol       Date:  2008-04-23       Impact factor: 4.130

Review 7.  Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.

Authors:  Julia Bohlius; Kurt Schmidlin; Corinne Brillant; Guido Schwarzer; Sven Trelle; Jerome Seidenfeld; Marcel Zwahlen; Mike J Clarke; Olaf Weingart; Sabine Kluge; Margaret Piper; Maryann Napoli; Dirk Rades; David Steensma; Benjamin Djulbegovic; Martin F Fey; Isabelle Ray-Coquard; Volker Moebus; Gillian Thomas; Michael Untch; Martin Schumacher; Matthias Egger; Andreas Engert
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

8.  Anaemia: a rare but neglected problem among Finnish patients receiving chemotherapy for solid tumours.

Authors:  Pirkko-Liisa Kellokumpu-Lehtinen; Ulla Puistola; Outi Paija; Eeva Taimela; Outi Hirvonen; Sari Raassina; Henrik Riska
Journal:  Support Care Cancer       Date:  2010-01-26       Impact factor: 3.603

9.  Erythropoietin update 2011.

Authors:  Mariusz Kowalczyk; Maciej Banach; Dimitri P Mikhailidis; Jacek Rysz
Journal:  Med Sci Monit       Date:  2011-11

10.  Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway.

Authors:  Z Wang; Q Ma; Q Liu; H Yu; L Zhao; S Shen; J Yao
Journal:  Br J Cancer       Date:  2008-10-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.